TITLE

RESEARCH ROUNDUP

AUTHOR(S)
Cowan, Helen
PUB. DATE
July 2017
SOURCE
British Journal of Cardiac Nursing;Jul2017, Vol. 12 Issue 7, p322
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
No abstract available.
ACCESSION #
124182578

 

Related Articles

  • Play of Chance Versus Concerns Regarding Dipeptidyl Peptidase-4 Inhibitors: Heart Failure and Diabetes. Sanon, Vani P.; Sanon, Saurabh; Pham, Son V.; Chilton, Robert // Clinical Diabetes;Summer2014, Vol. 32 Issue 3, p121 

    The article examines the occurrence of heart failure syndrome in diabetes based on the result of clinical trials of cardiovascular (CV) disease patients who were given dipeptidyl peptidase-4 (DPP-4). The first trial evaluated the safety and efficacy of the saxagliptin in patients with diabetes...

  • DPP-4 inhibitors: Safety and efficacy in treatment of T2D.  // Diabetes Digest;2012, Vol. 11 Issue 3, p143 

    The article presents a brief summary of a study by T. Karagiannis and colleagues to determine the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors as compared with other oral hypoglycaemic medications in people with type 2 diabetes.

  • Prescribed with gusto despite "uncertain" benefits. Holmes, Patrick // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;4/28/2012, Vol. 344 Issue 7854, p27 

    A letter to the editor is presented in response to the article "The role of dipeptidyl peptidase-4 inhibitors" by D. Lasserson and J. Mant in the March 12, 2012 issue.

  • DPP-4 inhibitor linagliptin launched for adults with T2D.  // Diabetes Digest;2011, Vol. 10 Issue 4, p230 

    The article reports on the launch of linagliptin, a dosage strength dipeptidyl peptidase-4 (DPP-4) inhibitor for people with renal impairment and type 2 diabetes (T2D), in Great Britain in September 2011.

  • Review exaggerated benefits. S Scheffel, Rafael S.; D Schaan, Beatriz D.; Tsapas, Apostolos; Karagiannis, Thomas; Paschos, Paschalis; Paletas, Konstantinos; Matthews, David R. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;4/28/2012, Vol. 344 Issue 7854, p27 

    A letter to the editor and a reply are presented in response to the article "Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis" by Thomas Karagiannis and colleagues in the March 12, 2012 issue.

  • The role of dipeptidyl peptidase-4 inhibitors: Will be clearer once ongoing trials are complete. Lasserson, Daniel; Mant, Jonathan // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/31/2012, Vol. 344 Issue 7850, p7 

    The authors reflect on the systematic review and meta-analysis presented by Karagiannis and colleagues on the role of oral hypoglycaemic drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors in treating patients with type 2 diabetes. The authors provide data on the study of researchers wherein...

  • Tradjenta, a Drug for Type 2s, Now on US Market.  // Diabetes Health;Oct/Nov2011, Vol. 20 Issue 5, p29 

    The article offers information on type 2 diabetes drug Tradjenta from Boehringer Ingelheim and Eli Lilly.

  • Initial results indicate that the novel DPP-4 inhibitors have potential cardiovascular benefits. Evans, Marc // Diabetes Digest;2013, Vol. 12 Issue 1, p49 

    This section presents overviews of research studies published in cardiovascular journals. H. R. Patil et al. examined the effect if dioeotidyl peptidase-4 (DPP-4) inhibitors on cardiovascular (CV) events. The effects niacin on glucose levels, coronary stenosis progression and clinical events in...

  • Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Keating, Gillian // Drugs;May2015, Vol. 75 Issue 7, p777 

    The dipeptidyl peptidase-4 inhibitor alogliptin (Nesina, Vipidia) is approved in numerous countries worldwide for the treatment of type 2 diabetes mellitus. Fixed-dose combinations of alogliptin/metformin (Kazano, Vipdomet) and alogliptin/pioglitazone (Oseni, Incresync) are also available. This...

  • Long-term safety of DPP-4 inhibitors in treatment of T2D.  // Diabetes Digest;2012, Vol. 11 Issue 3, p142 

    The article discusses a study by K. Gooßen and S. Gräber which investigates long-term safety of dipeptidyl peptidase-4 (DPP-4) inhibitors in the long-term treatment of people with type 2 diabetes.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics